Skip to main content
OpenTrials
Completed

NCT Number: NCT04351295

Efficacy of Faviprevir in COVID-19 Treatment

Faviprevir in COVID-19 treatment

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Tanta University, Ainshams University

Tanta, 35111, Egypt

About this study

Clinical Study Evaluating the Efficacy of Faviprevir in COVID-19 treatment

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with covid 19

Exclusion criteria

  • Allergy or contraindications to faviprevir

Treatment and study plan

Favipiravir

Drug

Favipiravir

Other names: Faviprevir

Chloroquine

Drug

chloroquine oral tablets

Primary outcomes

  1. Number of patients with mortality or need for mechanical ventilation

    Time frame: 6 months

    Number of patients with mortality or need for mechanical ventilation

Sponsors and collaborators

Lead sponsor

Tanta University

Other

Registry information

Official study title

Clinical Study Evaluating the Efficacy of Faviprevir in COVID-19 Treatment

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Apr 17, 2020
Registry last updated
Nov 1, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.